Solid-dominant lung cancer histology no barrier to segmentectomy

Complete resection with segmentectomy is as effective as lobectomy for patients with solid-dominant clinical stage IA lung adenocarcinoma, Japanese study findings suggest.

Recurrence-free survival (RFS) did not significantly differ between the 286 patients who underwent lobectomy and the 41 patients who had segmentectomy, with 3-year rates of 84.4% and 84.8%, respectively.

Nor did the pattern of local (5.6 vs 7.3%) or distant (9.1 vs 4.9%) recurrence significantly differ between the lobectomy and segmentectomy surgical groups, report Morihito Okada, from Hiroshima University, and colleagues.

Three-year rates of RFS were also comparable after lobectomy and segmentectomy for 182 patients with mixed ground-glass opacity tumours (91.0 and 85.0%, respectively) and 145 patients with pure solid tumours (76.8 and 84.7%, respectively).

Indeed, in multivariate analysis, RFS was predicted only by solid tumour size on preoperative high-resolution computed tomography (hazard ratio [HR]=1.67) and the maximum standardised uptake value during preoperative F-18-fluorodeoxyglucose positron emission tomography/computed tomography (HR=1.18).

By contrast, gender, tumour type and surgical procedure had no significant impact on patient outcome, say Okada et al in the European Journal of Cardio-thoracic Surgery.

“Segmentectomy for solid-dominant clinical stage IA lung adenocarcinoma showed RFS equivalent to that of standard lobectomy in our selected patients”, the researchers conclude.

“Segmentectomy can be performed even for a pure solid tumour under strict intraoperative lymph node examination.”

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Sanford Health launches solid tumor oncolytic virus clinical trial